<DOC>
	<DOCNO>NCT00549744</DOCNO>
	<brief_summary>Subjects attend unit out-patient visit Day 1 , Day 7 , Day 14 Day 15 treatment period . The washout period treatment period minimum 10 day maximum 28 day . Subjects participate 3 treatment period .</brief_summary>
	<brief_title>Clinical Endpoint Trial Investigating Once Daily Bronchodilator Dosing</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>6- ( ( 3- ( ( dimethylamino ) carbonyl ) phenyl ) sulfonyl ) -8-methyl-4- ( ( 3-methyloxyphenyl ) amino ) -3-quinolinecarboxamide</mesh_term>
	<criteria>Subjects clinically stable persistent mild/moderate asthma within 4 week precede screen visit , exclusion significant pulmonary disease ( e.g . chronic bronchitis , emphysema , bronchiectasis , cystic fibrosis bronchopulmonary dysplasia ) Subjects screen prebronchodilator FEV1 70 % predict ( abstained bronchodilator require period ) . Predicted value base NHanes normal range During screen visit , subject must demonstrate presence reversible airway disease , define increase FEV1 12.0 % max three screen measure absolute change 150 mL within 30 minute follow single 400 mg salbutamol dose Male female age 18 65 year age.A female eligible enter participate study : 1 . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include female post menopausal . For purpose study , post menopausal define 1 year without menses ( FSH/LH also test confirm menopausal status ) ; 2 . Child bear potential , negative pregnancy test ( urine ) screen predose Day 1 , agree one follow acceptable contraceptive method use consistently correctly ( i.e. , accordance approve product label instruction physician duration study screen visit followup contact ) : Complete abstinence intercourse screen visit , throughout trial 7 ( ~5 halflives GSK256066 ) day completion trial ; Male partner sterile prior female subject 's entry study , Implants levonorgestrel insert least 1 month prior study medication administration beyond third successive year follow insertion ; Injectable progestogen administer least 1 month prior study medication administration administer 1 month follow study completion ; Oral contraceptive ( combine progestogen ) administer least one monthly cycle prior study medication administration ; The contraceptive transdermal patch , Ortho Evra ( subject less 89kg ) ; Doublebarrier method spermicide plus mechanical barrier ( e.g. , spermicide plus male condom spermicide female diaphragm . Recent data show certain doublebarrier method failure rate 1 % [ Trussell , 2003 ] . Specifically , spermicide plus mechanical barrier ( e.g. , spermicide plus male condom female diaphragm ) . This provide validated confirmation failure rate doublebarrier method . Thus method meet state criterion acceptable contraception EMEA guideline [ CPMP/ICH/285/95 , 2000 ] ; Condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository ; An intrauterine device ( IUD ) intrauterine system ( IUS ) , insert qualified physician , publish data show high expected failure rate le 1 % per year ; ( IUDs meet criterion ) Acceptable IUDs : Tcu380A ( Paragard ) , TCU380 Slimline ( Gyne T Slimline ) , Tcu220C , MULTILOAD250 ( MLCu250 ) 375 , NOVA T CUNOVAT ( Novagard ) , Levonorgesterol ( LNG20 ) Intrauterine System ( Mirena/Levonova ) , FlexiGard 330/CuFix PP330 ( Gynefix ) . The device must insert least 2 week prior Screen visit , remain throughout study followup phase study Any method publish data show high expected failure rate le 1 % per year . Body weight 50 kg Body mass index within range 1931 kg/m2 inclusive Subjects current nonsmoker , use inhale tobacco product ( snuff permit ) 12 month period precede screen visit pack history £ 10 pack year No significant abnormality 12lead ECG screening , include follow requirement : Ventricular rate ≥ 40 beat per minute PR interval ≤ 200 m Q wave &lt; 30 m ( 50 ms permit lead III ) QRS interval ≥ 60 m ≤ 110 m QTc interval &lt; 450msec ( QTcB QTcF ; machine manual reading ) base single ECG value , average three ECGs obtain brief recording period Able provide write informed consent The subject able understand comply protocol requirement , instruction protocolstated restriction Demonstrated ability use inhaler device satisfactory repeatable manner As result medical interview , physical examination screen investigation , principle investigator delegate physician deems subject unsuitable study . Subjects must systolic blood pressure 145 mmHg diastolic pressure 85 mmHg unless Investigator confirm satisfactory age The subject treat diagnosed depression within six month screen history significant psychiatric illness Past present disease , judge investigator , may affect outcome study . These disease include , limited , cardiovascular disease , malignancy , hepatic disease , renal disease* , haematological disease , neurological disease , endocrine disease pulmonary disease ( include confine chronic bronchitis , emphysema , bronchiectasis pulmonary fibrosis ) Subjects require normal serum creatinine clearance value screen [ calculate serum creatinine predict equation use CockcroftGualt formula ] . If creatinine clearance value great upper limit normal determine local laboratory reference range , Investigator determine whether clinically significant find would preclude participation Subject history atrial arrhythmia ventricular arrhythmia Pregnant nursing female Women childbearing potential unwilling unable use appropriate method contraception least two week prior first dose study medication ; continue final pregnancy test perform ( less 150 hour treatment Subjects history lifethreatening asthma , define asthma episode require intubation and/or associate either respiratory arrest hypoxic seizures Asthma exacerbation require treatment oral corticosteroid : exacerbation within 3 month screen visit two exacerbation within 6 month screen visit admittance hospital asthma exacerbation within 1 year screen visit Subjects suffer upper low respiratory tract infection within 4 week screen visit History sensitivity study medication , component thereof history drug allergy , opinion physician responsible , contraindicate participation Subjects unable washout follow protocol define prohibited medication within define time screen : Oral corticosteroid Inhaled , intranasal topical steroid Long act beta agonist Short act beta agonists The subject take prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator Sponsor medication interfere study procedure compromise subject safety History alcohol/drug abuse dependence within 12 month study Abuse alcohol define average weekly intake great 21 unit average daily intake great 3 unit ( male ) define average weekly intake great 14 unit average daily intake great 2 unit ( female ) . 1 unit equivalent halfpint ( 220mL ) beer 1 ( 25ml ) measure spirit 1 glass ( 125ml ) wine ) The subject participate clinical trial receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication Exposure four new chemical entity within 12 month prior first dose day Donation blood excess 500 mL within 56 day period prior dose A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen The subject test positive HIV antibody ( test accord site SOPs ) The subject positive prestudy urine drug/ urine alcohol screen . A minimum list drug screen include Amphetamines , Barbiturates , Cocaine , Opiates , Cannabinoids Benzodiazepines</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>ASTHMA</keyword>
	<keyword>CLINICAL ENDPOINT ,</keyword>
</DOC>